Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Leigh-Ann Naccari

Internal Medicine Baton Rouge, LA Medical Doctor

NPI 1538663976 CMS profile 9924793

5000 Hennessy Blvd, Baton Rouge, LA 70808

Open in the dashboard

General payments

$5,014

284 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leigh-Ann Naccari of Baton Rouge, LA is reported in the CMS Open Payments database as having received $5,014 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,057 55
2024 General $1,948 122
2023 General $1,797 95
2022 General $185 10
2021 General $28 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leigh-Ann Naccari
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Leigh-Ann Naccari were reported at $1,057. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Leigh-Ann Naccari Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $28 $135 $37–$521 $132
2022 $185 $141 $42–$496 $149
2023 $1,797 $149 $45–$519 $160
2024 $1,948 $154 $47–$537 $164
2025 $1,057 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $1,072 80 payments
  2. AstraZeneca Pharmaceuticals LP $726 23 payments
  3. Lilly USA, LLC $435 33 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $413 25 payments
  5. Novo Nordisk Inc $295 22 payments
  6. GlaxoSmithKline, LLC. $264 14 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $254 14 payments
  8. Exact Sciences Corporation $229 11 payments
  9. Janssen Pharmaceuticals, Inc $162 9 payments
  10. AbbVie, Inc. $135 5 payments
  11. Other $1,030 48 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,920 283 payments
  2. Education $94 1 payment
Products named General payments · program years 2021–2025
  1. NURTEC ODT $559 52 payments
  2. FARXIGA $555 12 payments
  3. ELIQUIS $476 38 payments
  4. Kerendia $413 25 payments
  5. COMIRNATY $405 22 payments
  6. PREVNAR 20 $350 19 payments
  7. ABRYSVO $338 18 payments
  8. PAXLOVID $238 18 payments
  9. MOUNJARO $236 14 payments
  10. Ozempic $215 16 payments
  11. Other $3,634 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 100 drugs

Part D claims

4,790

Median for Internal Medicine: 777

Drug cost

$356,459

Median for Internal Medicine: $73,373

Branded share of claims

17.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 67 $82,540
Ozempic Semaglutide Brand 47 $78,885
Jardiance Empagliflozin Brand 66 $60,775
Eliquis Apixaban Brand 49 $34,159
Rybelsus Semaglutide Brand 18 $21,998
Januvia Sitagliptin Phosphate Brand 28 $21,488
Repatha Sureclick Evolocumab Brand 15 $13,516
Atorvastatin Calcium Generic 310 $2,653
Levothyroxine Sodium Generic 236 $1,911
Gabapentin Generic 150 $1,471

The 10 drugs with the highest cost, of 100 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$40,297

Of which drugs: $3,427

Medicare patients

182

Average age 75

Services billed

608

126 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 51%
Diabetes 26%
Depression 26%
Ischemic heart disease 25%
Chronic kidney disease 24%
Atrial fibrillation 19%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $99
  • Boehringer Ingelheim Pharmaceuticals, Inc. $60
$158 66 —
NURTEC ODT
  • PFIZER INC. $111
$111 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $110
$110 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $96
$96 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record